Here's your invitation to this year's Endpoints 11 awards. Let's celebrate the best of biotech together
Over in the public market, we’re watching the wheat being remorselessly separated from the chaff as the biotech sector went from everyone’s darling to the orphan child of Wall Street. That was inevitable. But while there’s been a knock-on effect in the venture investing side, we’re seeing clear evidence that big players are sticking with their game plan: Major technological breakthroughs are opening doors to biotech startups that didn’t exist five years ago — and the sophisticated investors don’t want to miss out.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.